CORT Corcept Therapeutics Incorporated

13.1
-0.03  -0%
Previous Close 13.13
Open 13.1
Price To Book 4.47
Market Cap 1,497,077,275
Shares 114,280,708
Volume 932,286
Short Ratio
Av. Daily Volume 989,679
Stock charts supplied by TradingView

NewsSee all news

  1. Corcept Therapeutics Announces Third quarter 2019 Financial Results and provides corporate update

    MENLO PARK, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  2. Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

    MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 7, 2019.

  3. Corcept Therapeutics Appoints Kimberly Park to Board of Directors

    MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  4. Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing's Syndrome

    MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Approved February 17, 2012.
Corlux - Korlym
Cushing's Syndrome
Phase 1/2 presented at ASCO June 3, 2019.
Relacorilant plus Abraxane
Solid tumors - cancer
Phase 3 commencement of enrolment announced November 19, 2018.
Relacorilant
Cushing’s syndrome
Phase 2 trial ongoing - noted May 9, 2019.
Relacorilant plus Abraxane
Ovarian cancer
Phase 2 trial to be initiated in 2020.
CORT118335
Nonalcoholic steatohepatitis (NASH)
Phase 1/2 dosing ongoing - May 9, 2019.
CORT125281 plus Xtandi
Castration-resistant prostate cancer (CRPC)
Phase 1b data due later in 2019.
CORT118335
Prevention of antipsychotic-induced weight gain
Phase 2 trial to be initiated 2H 2019.
CORT118335
Reversal of antipsychotic-induced Weight Gain (AIWG)
Phase 3 trial planned.
Relacorilant plus nab-paclitaxel
Pancreatic cancer

Latest News

  1. Corcept Therapeutics Announces Third quarter 2019 Financial Results and provides corporate update

    MENLO PARK, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  2. Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

    MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) today announced it will report third quarter financial results and provide a corporate update on November 7, 2019.

  3. Corcept Therapeutics Appoints Kimberly Park to Board of Directors

    MENLO PARK, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic

  4. Corcept Therapeutics Announces Allowance of Additional Patent Covering the Use of Korlym to Treat Patients With Cushing's Syndrome

    MENLO PARK, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ:CORT) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance for a patent